AAP Endorses Early Peanut Introduction for High-Risk Infants

Troy Brown

August 26, 2015

Clinicians should recommend introducing peanut-containing foods into the diets of high-risk infants aged between 4 and 11 months, according to a new consensus statement from 10 medical organizations in Europe and the United States. The consensus statement will be published online August 31 in Pediatrics.

"There will be more extensive guidelines in the near future from the [National Institute of Allergy and Infectious Diseases] Working Group and [European Academy of Allergy and Clinical Immunology] Guidelines Group and their multidisciplinary stakeholders. These groups will consider all the available data and determine whether there is sufficient evidence to apply prevention strategies to the general population," the authors write.

"However, engagement of the primary care, allergy, and dermatology communities to rapidly implement these findings and change the culture of early feeding practices is essential, and the forthcoming [National Institute of Allergy and Infectious Diseases] Working Group's and [European Academy of Allergy and Clinical Immunology] Guidelines Group's documents will better clarify a best-practices approach."

The current consensus statement is based on data from the Learning Early About Peanut Allergy (LEAP) trial — a randomized controlled trial — and existing guidelines.


  • Level 1 scientific evidence from the LEAP trial shows that clinicians should recommend the introduction of peanut-containing foods into the diets of "high-risk" infants aged between 4 and 11 months in countries with prevalent peanut allergy. Delaying this introduction can be associated with an increased risk for peanut allergy.

  • Consider evaluation by an allergist or physician trained in the management of allergic diseases in this age group for infants with early-onset atopic disease, such as severe eczema or egg allergy. Such evaluation might include peanut skin testing, in-office observed peanut ingestion, or both. The healthcare provider can perform an observed peanut challenge for infants with evidence of a positive peanut test response to determine whether the infant is clinically reactive before introducing peanut at home. The LEAP study protocol included both strategies.

  • Infants in the LEAP trial were randomized to consume peanut, ingesting a median of 7.7 grams (g) of peanut protein (interquartile range, 6.7 g –8.8 g) per week during the first 2 years of the trial compared with a median of 0 g in the avoidance group. Adherence in the trial was 92%.

"Although the outcome of the LEAP regimen was excellent, the study does not address use of alternative doses of peanut protein, minimal length of treatment necessary to induce the tolerogenic effect, or potential risks of premature discontinuation or sporadic feeding of peanut," the authors conclude.

The authors have disclosed no relevant financial relationships.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.